OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2017.7152 OL-0-0-7152 Articles Serum levels of anti-sperm-associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma RenBiqiong 1 2 3 ZouGuoying 1 2 3 XuFei 1 2 HuangYiran 2 XuGuofeng 2 3 HeJunyu 1 2 3 LiYong 2 3 ZhuHaowen 2 3 YuPing 3 Clinical Laboratory, Hunan Provincial Second People's Hospital, Changsha, Hunan 410007, P.R. China Clinical Medical School, Hunan University of Chinese Medicine, Changsha, Hunan 410007, P.R. China Department of Immunology, School of Basic Medicine, Central South University, Changsha, Hunan 410078, P.R. China Correspondence to: Professor Biqiong Ren, Clinical Laboratory, Hunan Provincial Second People's Hospital, 427 Furong Road, Changsha, Hunan 410007, P.R. China, E-mail: 13808481211@163.com 12 2017 09 10 2017 14 6 7608 7614 24012016 19012017 Copyright © 2017, Spandidos Publications 2017

At present, there is a high incidence of viral hepatitis and high mortality rates due to hepatocellular carcinoma (HCC) in China. In the current study, the quantification of antibodies against the cancer-testis antigen sperm-associated antigen 9 (SPAG9), alone and combined with α-fetoprotein (AFP), were evaluated as biomarkers for the diagnosis of HCC. The levels of anti-SPAG9 antibody and AFP were quantified in serum samples from patients with HCC and hepatitis or cirrhosis, as well as healthy volunteers. The results revealed that the serum levels of anti-SPAG9 immunoglobulin G antibody in patients with HCC were significantly higher compared with those in patients with hepatitis/cirrhosis and healthy controls. Using receiver operator characteristic curves, the area under the curve (AUC, 0.870) of SPAG9 as a diagnostic marker of HCC was significant [P<0.001; 95% confidence interval (CI), 0.793–0.947], whereas the AUC of AFP was 0.832 (P<0.001; 95% CI, 0.736–0.928). Serum anti-SPAG9 antibody levels exhibited significant potential for the differential diagnosis of HCC, with an AUC value of 0.729, (P=0.008; 95% CI, 0.559–0.899). Similarly, serum AFP levels exhibited significant value for the differential diagnosis of HCC, with an AUC value of 0.842 (P<0.001; 95% CI, 0.732–0.953). When combined with quantification of AFP, the diagnostic sensitivity and specificity of anti-SPAG9 levels were increased. In summary, the results suggested that anti-SPAG9 antibody is a potential early diagnostic marker of HCC.

 sperm-associated antigen 9 autoantibody biomarker hepatocellular carcinoma diagnosis Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major risk factors for the development of human hepatocellular carcinoma (HCC) (1–3). The incidence of HCC in China is ~100/100,000 population, and a principal component of the attributable risk is chronic HBV infection (4), with >50% of the global HCC burden attributed to HBV (5). In China, ~10% of patients with HCC suffer from HCV infection, and certain patients have HBV and HCV co-infections (6). In the USA, Europe and Japan, >50% of current cases of HCC are attributable to HCV infection, and the majority of these patients have cirrhosis (7–9). The time from initial diagnosis of chronic hepatitis to the development of HCC may span several decades; once cirrhosis is established, HCC develops at a yearly rate of 1–4% (10).

In China, the majority of patients with HCC present with advanced-stage disease, and HCC has become the second leading cause of mortality (11). Early diagnosis relies on non-invasive biomarkers, imaging and clinical parameters, with markers such as α-fetoprotein (AFP), the proportion of the fucosylated isoform of AFP to total AFP, AFP-L3 and des-gamma-carboxy-prothrombin (DCP) being Food and Drug Administration-approved for use in the surveillance of high-risk populations (12,13). However, the clinical value of these biomarkers is a subject of debate (14). In Japan, three biomarkers are combined for surveillance (15,16), and this combined testing has a high level of sensitivity and specificity (17,18). In China, AFP is the only serum biomarker routinely used for HCC diagnosis (19). Up to 50% of patients with HCC have a serum AFP level of <20 ng/ml (20), and therefore are not correctly diagnosed when AFP is the sole biomarker used to screen for HCC (21).

In the current study, the efficacy of the cancer-testis antigen (CTA) sperm-associated antigen 9 (SPAG9), alone and combined with AFP, was evaluated for use in the diagnosis of HCC caused by HBV or HCV infections.

CTAs include the melanoma antigen family, the synovial sarcoma X family, cancer/testis antigen 2, G antigen 1, cancer/testis associated protein CTp11 and cancer/testis antigen 1B. The expression of these antigens is normally restricted to the testis, but these antigens are also expressed in tumor tissues (22–24). Several studies have revealed that CTAs are highly expressed in the tumor tissue of patients with HCC (25–27). SPAG9 belongs to the c-Jun-NH2 terminal kinase-interacting protein family (28). Proteins from this family function in cell growth, proliferation, apoptosis and tumor development (29,30), and are expressed in renal cell carcinoma, and ovarian, cervical, breast, thyroid and colorectal cancer tissues, SPAG9 provokes a strong humoral immune response, and its autoantibody can be detected in the peripheral blood of patients with the aforementioned types of cancer (21–35). The current study hypothesized that anti-SPAG9 antibody may be detected in the peripheral blood of patients with HCC, and that, in combination with serum AFP levels, it may provide a reliable diagnostic test for HCC, particularly for AFP-negative patients.

 Materials and methods <sec> <title>Patients

A total of 31 cases of HCC caused by HBV or HCV infections, 41 cases of hepatitis or cirrhosis caused by HBV or HCV without HCC, and 37 normal healthy blood donors were enrolled at Hunan Provincial Second People's Hospital (Changsha, China) from March 2013 to May 2014. HCC was diagnosed as previously reported (18). The inclusion criteria were no prior anti-cancer treatment (therapeutic agents, radiotherapy or chemotherapy) and positivity for HBV or HCV infection. The exclusion criteria were as follows: Active liver disease (non-cancerous hepatitis or cirrhosis), pregnancy, reproductive system embryonic tumors or metastatic liver cancer. The cases with hepatitis or cirrhosis without HCC included eight patients with cirrhosis. Patient characteristics are summarized in Tables I and II. Peripheral blood samples were collected from patients and controls. Serum was separated by centrifuging blood at 1,000 × g for 10 min at 25°C. Serum samples were stored at −80°C prior to analysis.

 SPAG9 ELISA assay

Recombinant human SPAG9 protein (r-hSPAG9; Abnova, Taipei, Taiwan) was used as antigen to establish an ELISA to detect serum anti-SPAG9 immunoglobulin IgG antibody. Microtiter plates were coated with r-hSPAG9 (100 ng/well) in 50 mM PBS (pH 7.4) at 4°C overnight. The plates were washed three times with PBS and blocked with 5% bovine serum albumin (Zhejiang Tianhang Biotechnology Co., Ltd, Huzhou, China) in PBS for 2 h at 37°C. Post-blocking, the plates were incubated with a 1:10 dilution (0.05 M carbonate buffer, pH 9.6) of patient serum. Bound antibodies were detected after incubation with a mouse anti-human antibody conjugated to horseradish peroxidase (Beijing Beier Biological Engineering Co., Ltd., Beijing, China; cat. no. 20141001) at an optimized dilution of 1:5,000 in PBS for 2 h at 37°C. Enzyme activation was performed with 0.05% orthophenylenediamine (Beijing Beier Biological Engineering Co., Ltd.) in 50 mM citrate phosphate buffer (pH 5.0) with 0.06% hydrogen peroxide as the substrate. The reaction was terminated with 50 µl of 5 M H2SO4, and the absorbance was read at a wavelength of 450 nm using a microplate spectrophotometer with 630 nm as a reference filter. The intra- and inter-assay coefficients of variation were 2.3 and 8.6%, respectively.

 AFP chemiluminescence assay

Serum AFP levels were determined using the ADVIA Centaur XP Immunoassay System (Siemens AG, Munich, Germany), and the quality control materials were provided by Bio-Rad Laboratories, Inc. (Hercules, CA, USA).

 Statistical analysis

The Kruskal-Wallis, Mann-Whitney U, independent-samples t and χ2 tests, as well as receiver operator characteristic (ROC) curve analysis were performed using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA). Results were presented as the mean ± standard deviation. Anti-SPAG9 antibody levels in patients with HCC, patients with hepatitis/cirrhosis and healthy individuals were compared using the Mann-Whitney U test with Bonferroni correction. α=0.0167 and P<0.0167 were considered to indicate a statistically significant difference. Positivity of anti-SPAG9 antibody in patients with HCC, patients with hepatitis/cirrhosis and healthy individuals was compared using the χ2 test and partitioned χ2 tests. α=0.0125 and P<0.0125 were considered to indicate a statistically significant difference. The percentages of patients who were positive for a marker were compared using a χ2 test with an inspection level of 0.05 considered to indicate a statistically significant difference. For multiple comparisons, the χ2 test was used, with an inspection level corrected to 0.0125 considered to indicate a statistically significant difference. For other comparisons performed with an independent-samples t test, P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Levels of serum anti-SPAG9 antibody in patients with HCC and hepatitis/cirrhosis

The mean of the signal intensity in the SPAG9 ELISA for patients with HCC (0.590±0.274) was significantly higher than that for patients with hepatitis/cirrhosis (0.445±0.515) and healthy individuals (0.189±0.115; P<0.001). Data from all patients and individuals are plotted in Fig. 1A. Using a cut-off value of 0.42, 71.0% of the patients with HCC were positive for the SPAG9 antigen, whereas 26.8% of patients with hepatitis/cirrhosis and 8% of healthy individuals were positive for the antigen based on this cut-off (Fig. 1B). The mean absorbance (0.89±0.810) of anti-SPAG9 immunoglobulin IgG antibody in patients with cirrhosis was significantly higher compared with that of patients with hepatitis (0.337±0.355) and healthy individuals (P<0.001; Fig. 1C).

 Levels of serum anti-SPAG9 antibody in patients with various stages of HCC

The mean of the signal intensity in the SPAG9 ELISA in patients with stage II HCC (0.647±0.310) was significantly higher (P<0.01) compared with that in patients with stage III and IV disease (0.468±0.153; Fig. 2A). Of the stage II patients with HCC, 75% were positive for SPAG9, whereas 63.6% of stage III and IV patients were positive for SPAG9 (Fig. 2B). This difference was not significant.

 Sensitivity and specificity of anti-SPAG9 antibody alone and in combination with AFP for HCC diagnosis

The sensitivity and specificity of anti-SPAG9 antibody alone for the diagnosis of HCC were 71.0 and 87.3%, respectively. The sensitivity was higher compared with that of AFP alone (64.5%), whereas the specificity was lower compared with that of AFP alone (94.5%). When anti-SPAG9 and AFP were used in parallel, the sensitivity and specificity were 90.3 and 83.6%, respectively. In series, with the anti-SPAG9 antibody test conducted first, the sensitivity and specificity were 45.2 and 98.2%, respectively (Table III). The ROC curve for serum anti-SPAG9 antibody had an AUC value of 0.870 [P<0.001; 95% confidence interval (CI), 0.793–0.947]. The ROC curve for AFP had an AUC value of 0.832 (P<0.001; 95% CI, 0.736–0.928; Fig. 3A).

The sensitivity and specificity of anti-SPAG9 antibody alone in the differential diagnosis of HCC were 71.0 and 77.8%, which was higher in sensitivity and lower in specificity than the value obtained for AFP alone (64.5 and 83.3%, respectively). A combination of anti-SPAG9 antibody with AFP in parallel obtained a sensitivity and specificity of differential diagnosis of 90.3 and 66.7%, respectively. When anti-SPAG9 antibody and AFP were used in series, the sensitivity and specificity of diagnosis were 45.2 and 94.4%, respectively (Table IV). ROC curves for serum anti-SPAG9 antibody had an AUC value of 0.729 (P<0.001; 95% CI, 0.559–0.899). The ROC curve for AFP had an AUC value of 0.842 (P<0.001; 95% CI, 0.732–0.953; Fig. 3B).

 Anti-SPAG9 antibody levels distinguish between patients with HCC and with hepatitis/cirrhosis

Anti-SPAG9 antibodies were detected in 71.0% of patients with HCC, whereas AFP was detected in 64.6% of patients; this difference was not significant (P<0.05). Of patients with hepatitis or cirrhosis, 26.8% tested positive for anti-SPAG9, whereas 13% were positive for AFP, and this difference was significant (P<0.01). In healthy controls, 8.0% had serum antibodies against SPAG9 and 3.0% expressed AFP (Figs. 1B and 4). The proportion of male patients with HCC that were positive for serum anti-SPAG9 antibody was significantly lower than the proportion of female patients. By contrast, male patients with HCC were more likely to test positive for serum AFP compared with female patients (Fig. 5).

 Discussion

China is a country with a high incidence of viral hepatitis and high mortality rates due to HCC. In China, AFP is the only serum biomarker included in the diagnostic criteria for HCC, whereas other countries suggest the use of a combination of non-invasive biomarkers for surveillance in high-risk populations. At present, AFP is the most effective diagnostic indicator for HCC (36). A recent meta-analysis of the diagnostic value of AFP in HCC determined a pooled sensitivity of 66%, a specificity of 86% and an AUC value of 0.87 (37). The combination of AFP with DCP produced a sensitivity of 55% for the detection of early-stage HCC and 78% for the diagnosis of all stages of HCC, with cut-off values of 10 ng/ml for AFP and 5 ng/ml for DCP (38). The addition of AFP-L3 led to a further enhancement in sensitivity to 84% (39).

Anti-CTA antibodies are generally absent or present at a low frequency in healthy individuals, but are highly expressed by patients with cancer (40,41). The current study therefore hypothesized that a CTA may serve as a biomarker for HCC. The results revealed that the serum levels of anti-SPAG9 antibody had a diagnostic sensitivity of 71.0%, a specificity of 87.3% and an AUC value of 0.870 in patients with HCC. The combination of AFP with anti-SPAG9 antibody in parallel had a sensitivity of 90.3%; in series, the specificity was 98.2%. The level of serum anti-SPAG9 antibody was significantly higher in patients with HCC than in patients with hepatitis or cirrhosis and healthy controls. In addition, the serum anti-SPAG9 levels were significantly higher in patients with stage II HCC compared with those in patients with stage III or IV disease. These data indicate that anti-SPAG9 is a potential early diagnostic marker for HCC. As the current study evaluated a small cohort of patients, analyses of larger numbers of patients are required.

The liver is a sexually dimorphic organ, with sex variations in mitochondrial function, membrane lipid composition, microsomal enzyme activity, gene expression and immune responses (42). Sexual dimorphism of the liver alters the metabolism of drugs and toxins in males and females (43). This may at least partially explain the observed sex differences in anti-SPAG9 antibody expression in patients with HCC. In the current study, the proportion of male patients with HCC that were positive for serum anti-SPAG9 antibody was significantly lower compared with the proportion of female patients. By contrast, male patients with HCC were more likely to test positive for serum AFP compared with female patients. However, the number of female patients included in the present study was lower than the number of male patients, and further research requires an expansion in the study population.

Chronic hepatitis and cirrhosis are common precursor conditions of HCC. During the process of transition to malignancy, certain patients may develop autoantibodies that were not present during the precursory chronic liver disease phase (44). In the present study, the level of anti-SPAG9 IgG antibody in patients with cirrhosis was significantly higher compared with that in patients with hepatitis and healthy controls. This suggests that the strong humoral immune response triggered by SPAG9 in patients with cirrhosis may be an early marker for carcinogenesis. A greater number of patients with cirrhosis tested positive for SPAG9 compared with those who tested positive for AFP, indicating that the humoral immune response to SPAG9 may be an effective marker for early screening in populations with a high risk for HCC.

In conclusion, anti-SPAG9 antibody levels in the peripheral blood of patients with HCC were significantly higher compared with those in patients with hepatitis or cirrhosis and healthy controls. The potential value of SPAG9 as a diagnostic marker for HCC requires further investigation. Combining serum anti-SPAG9 antibody and AFP as disease markers may allow the early diagnosis of HCC.

 Acknowledgements

The present study was supported by a research grant from the Health Department of Hunan Province Foundation (grant no. B2011-099) and the Second People's Hospital of Hunan Province Key Specialized Foundation (grant no. 2014-005).

 Abbreviations SPAG9

sperm-associated antigen 9

 HCC

hepatocellular carcinoma

 AFP

α-fetoprotein

 CTA

cancer-testis antigen

 HBV

hepatitis B virus

 HCV

hepatitis C virus

 DCP

des-gamma-carboxy-prothrombin

 ROC

receiver operator characteristic

 References DhanasekaranRLimayeACabreraRHepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeuticsHepat Med41937201224367230 RaimondiSBrunoSMondelliMUMaisonneuvePHepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysisJ Hepatol5011421154200910.1016/j.jhep.2009.01.01919395111 PollicinoTSquadritoGCerenziaGCacciolaIRaffaGCraxiAFarinatiFMissaleGSmedileATiribelliCHepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infectionGastroenterology126102110200410.1053/j.gastro.2003.10.04814699492 ShermanMHepatocellular carcinoma: Epidemiology, risk factors, and screeningSemin Liver Dis25143154200510.1055/s-2005-87119415918143 ParkinDMThe global health burden of infection-associated cancers in the year 2002Int J Cancer11830303044200610.1002/ijc.2173116404738 SongPFengXZhangKSongTMaKKokudoNDongJYaoLTangWScreening for and surveillance of high-risk patients with HBV-related chronic liver disease: Promoting the early detection of hepatocellular carcinoma in ChinaBiosci Trends716201323524887 KiyosawaKUmemuraTIchijoTMatsumotoAYoshizawaKGadATanakaEHepatocellular carcinoma. Recent trends in JapanGastroenterology1275 Suppl 1S17S26200410.1053/j.gastro.2004.09.01215508082 Di BisceglieAMLyraACSchwartzMReddyRKMartinPGoresGLokASHussainKBGishRVan ThielDHHepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic statusAm J Gastroenterol9820602063200310.1016/S0002-9270(03)00552-514499788 DonatoFTaggerAChiesaRRiberoMLTomasoniVFasolaMGelattiUPorteraGBoffettaPNardiGHepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy. Brescia HCC studyHepatology26579584199710.1002/hep.5102603089303486 FattovichGGiustinaGDegosFTremoladaFDiodatiGAlmasioPNevensFSolinasAMuraDBrouwerJTMorbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patientsGastroenterology112463472199710.1053/gast.1997.v112.pm90243009024300 KudoMHanKHKokudoNChengALChoiBIFuruseJIzumiNParkJWPoonRTSakamotoMLiver cancer working group reportJpn J Clin Oncol1Suppl 40i19i27201010.1093/jjco/hyq123 BruixJShermanMAmerican Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An updateHepatology5310201022201110.1002/hep.2419921374666 European Association for the Study of the LiverEuropean Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinomaJ Hepatol56908943201210.1016/j.jhep.2011.12.00122424438 BruixJGoresGJMazzaferroVHepatocellular carcinoma: Clinical frontiers and perspectivesGut63844855201410.1136/gutjnl-2013-30662724531850 OmataMLesmanaLATateishiRChenPJLinSMYoshidaHKudoMLeeJMChoiBIPoonRTAsian pacific association for the study of the liver consensus recommendations on hepatocellular carcinomaHepatol Int4439474201010.1007/s12072-010-9165-720827404 MakuuchiMKokudoNAriiSFutagawaSKanekoSKawasakiSMatsuyamaYOkazakiMOkitaKOmataMDevelopment of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in JapanHepatol Res383751200810.1111/j.1872-034X.2007.00216.x18039202 SongPPGaoJJKokudoNDongJHTangW‘Knowledge into action’ exploration of an appropriate approach for constructing evidence-based clinical practice guidelines for hepatocellular carcinomaBiosci Trends6147152201222890164 SongPGaoJInagakiYKokudoNHasegawaKSugawaraYTangWBiomarkers: Evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and ChinaLiver Cancer23139201310.1159/00034622024159594 SongPTobeRGInagakiYKokudoNHasegawaKSugawaraYTangWThe management of hepatocel-lular carcinoma around the world: A comparison of guidelines from 2001 to 2011Liver Int3210531063201210.1111/j.1478-3231.2012.02792.x22432445 FarinatiFMarinoDDe GiorgioMBaldanACantariniMCursaroCRapacciniGDel PoggioPDi NolfoMABenvegnùLDiagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither?Am J Gastroenterol101524532200610.1111/j.1572-0241.2006.00443.x16542289 CuiZYuXGuoLWeiYZhengSLiWChenPZhuJPengJCombined analysis of serum alpha-fetoprotein and MAGE-A3-specific cytotoxic T lymphocytes in peripheral blood for diagnosis of hepatocellular carcinomaDis Markers35915923201310.1155/2013/90739424427779 SuriACancer testis antigens-their importance in immunotherapy and in the early detection of cancerExpert Opin Biol Ther6379389200610.1517/14712598.6.4.37916548764 GrizziFMirandolaLQehajajDCobosEFigueroaJAChiriva-InternatiMCancer-testis antigens and immunotherapy in the light of cancer complexityInt Rev Immunol34143153201510.3109/08830185.2015.101841825901859 SongMHChoiKUShinDHLeeCHLeeSYIdentification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinomaOncol Rep2817921798201210.3892/or.2012.200222941507 PengJRChenHSMouDCCaoJCongXQinLLWeiLLengXSWangYChenWFExpression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parametersCancer Lett219223232200510.1016/j.canlet.2004.07.02815723723 WangYHanKJPangXWVaughanHAQuWDongXYPengJRZhaoHTRuiJALengXSLarge scale identification of human hepatocellular carcinoma-associated antigens by autoantibodiesJ Immunol16911021109200210.4049/jimmunol.169.2.110212097419 YangXADongXYQiaoHWangYDPengJRLiYPangXWTianCChenWFImmunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissuesLab Invest85205213200510.1038/labinvest.370022015580283 GargMChaurasiyaDRanaRJagadishNKanojiaDDudhaNKamranNSalhanSBhatnagarASuriSSperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancerClin Cancer Res1314211428200710.1158/1078-0432.CCR-06-234017332284 JagadishNRanaRMishraDKumarMSuriASperm associated antigen 9 (SPAG9): A new member of c-Jun NH2-terminal kinase (JNK) interacting protein exclusively expressed in testisKeio J Med546671200510.2302/kjm.54.6616077255 YiFNiWLiuWPanXHanXYangLKongXMaRChangRSPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasionTumour Biol3428492855201310.1007/s13277-013-0845-523696027 GargMKanojiaDKhoslaADudhaNSatiSChaurasiyaDJagadishNSethAKumarRGuptaSSperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinomaCancer Res6882408248200810.1158/0008-5472.CAN-08-170818922895 GargMKanojiaDSalhanSSuriSGuptaALohiyaNKSuriASperm-associated antigen 9 is a biomarker for early cervical carcinomaCancer11526712683200910.1002/cncr.2429319326449 KanojiaDGargMGuptaSGuptaASuriASperm-associated antigen 9, a novel biomarker for early detection of breast cancerCancer Epidemiol Biomarkers Prev18630639200910.1158/1055-9965.EPI-08-062919190149 GargMKanojiaDSuriSGuptaSGuptaASuriASperm-associated antigen 9: A novel diagnostic marker for thyroid cancerJ Clin Endocrinol Metab9446134618200910.1210/jc.2009-070319820019 KanojiaDGargMGuptaSGuptaASuriASperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicityAm J Pathol17810091020201110.1016/j.ajpath.2010.11.04721356354 YaoMZhaoJLuFAlpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinomaOncotarget737023708201610.18632/oncotarget.691326784252 WanHGXuHGuYMWangHXuWZuMHComparison osteopontin vs. AFP for the diagnosis of HCC: A meta-analysisClin Res Hepatol Gastroenterol38706714201410.1016/j.clinre.2014.06.00825034355 ErtleJMHeiderDWichertMKellerBKueperRHilgardPGerkenGSchlaakJFA combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinomaDigestion87121131201310.1159/00034608023406785 HadziyannisESialevrisKGeorgiouAKoskinasJAnalysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levelsOncol Rep29835839201310.3892/or.2012.214723174906 TanEMAutoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesisJ Clin Invest10814111415200110.1172/JCI1445111714730 TanEMZhangJAutoantibodies to tumor-associated antigens: Reporters from the immune systemImmunol Rev222328340200810.1111/j.1600-065X.2008.00611.x18364012 DhirRNDworakowskiWThangavelCShapiroBHSexually dimorphic regulation of hepatic isoforms of human cytochrome p450 by growth hormoneJ Pharmacol Exp Ther3168794200610.1124/jpet.105.09377316160083 WaxmanDJHollowayMGSex differences in the expression of hepatic drug metabolizing enzymesMol Pharmacol76215228200910.1124/mol.109.05670519483103 ZhangJYZhuWImaiHKiyosawaKChanEKTanEMDe-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinomaClin Exp Immunol12539200110.1006/clim.2001.510011472419

(A) Anti-SPAG9 antibody in the serum of patients with HCC (n=31), patients with hepatitis or cirrhosis (n=41) and healthy controls (n=37), as detected using ELISA. (B) Percentage of patients and healthy controls positive for anti-SPAG9 antibody. (C) Anti-SPAG9 antibody in serum of patients with cirrhosis (n=8), patients with hepatitis (n=33) and healthy controls (n=37), as detected by ELISA. SPAG9, sperm-associated antigen 9; HCC, hepatocellular carcinoma.

(A) Anti-SPAG9 antibody in the serum of patients with stage II and with stage III or IV HCC, as detected using ELISA. (B) Percentage of patients with stage II or with stage III and IV HCC that were seropositive for anti-SPAG9 antibody. SPAG9, sperm-associated antigen 9; HCC, hepatocellular carcinoma.

(A) ROC curve analysis of the levels of serum anti-SPAG9 antibody and AFP for the diagnosis of HCC. (B) ROC curve analysis of the levels of serum anti-SPAG9 antibody and AFP to obtain a differential diagnosis of HCC. ROC; receiver operator characteristic; SPAG9, sperm-associated antigen 9; AFP, α-fetoprotein; HCC, hepatocellular carcinoma.

(A) Percentage of patients with HCC, hepatitis or cirrhosis and healthy controls that were seropositive for AFP. (B) Percentage of patients with hepatitis and cirrhosis that were seropositive for SPAG9 antibody and AFP. HCC, hepatocellular carcinoma; SPAG9, sperm-associated antigen 9; AFP, α-fetoprotein.

Percentage of male and female patients with hepatocellular carcinoma that were seropositive for SPAG9 and AFP. SPAG9, sperm-associated antigen 9; AFP, α-fetoprotein.

Characteristics of patients with HCC, hepatitis or cirrhosis and healthy controls.

Patient characteristic HCC (n=31) Hepatitis/cirrhosis (n=41) Healthy controls (n=35)
Age, years
  Mean ± SD (min, max) 56±12 (36,76) 41±16 (21,77) 53±10 (26,71)
Sex
  Male, % (n/total) 83.9 (26/31) 82.9 (34/41) 74.3 (26/35)
  Female, % (n/total) 16.1 (5/31) 17.1 (7/41) 25.7 (9/35)
Cancer stage
  II, % (n/total) 64.5 (20/31)
  II + IV, % (n/total) 35.5 (11/31)
Hepatitis B infection, n 28 36 0
Hepatitis C infection, n   3   5 0

SD, standard deviation; HCC, hepatocellular carcinoma; min, minimum; max, maximum.

Characteristics of patients with hepatitis and cirrhosis and healthy controls.

Patient characteristic Hepatitis (n=33) Cirrhosis (n=8) Healthy controls (n=35)
Age, years
  Mean ± SD (min, max) 41±13 (21,65) 55±12 (32,77) 53±10 (26,71)
Sex
  Male, % (n/total) 81.8 (27/33) 87.5 (7/8) 74.3 (26/35)
  Female, % (n/total) 18.2 (6/33) 12.5 (1/8) 25.7 (9/35)
Hepatitis B infection, n 28 8 0
Hepatitis C infection, n 5 0 0

SD, standard deviation; min, minimum; max, maximum.

Diagnostic value of anti-SPAG9 alone and in combination with AFP.

Item Sensitivity, % Specificity, % PPV, % NPV, % Positive likelihood ratio Negative likelihood ratio Youden index, %
Anti-SPAG9 antibody 71.0 87.3 75.9 84.2 5.58 0.33 58.2
AFP 64.5 94.5 87.0 82.5 11.83 0.38 59.1
Parallel use 90.3 83.6 75.7 93.9 5.52 0.12 74.0
Series use (anti-SPAG9, then AFP) 45.2 98.2 93.3 76.1 24.84 0.56 43.3

SPAG9, sperm-associated antigen 9; AFP, α-fetoprotein; PPV, positive predictive value; NPV, negative predictive value.

Differential diagnostic value of anti-SPAG9 alone and in combination with AFP.

Item Sensitivity, % Specificity, % PPV, % NPV, % Positive likelihood ratio Negative likelihood ratio Youden index, %
Anti-SPAG9 antibody 71.0 77.8 84.6 60.9 3.19 0.37 48.7
AFP 64.5 83.3 87.0 57.7 3.87 0.43 47.8
Parallel use 90.3 66.7 82.4 80.0 2.71 0.15 57.0
Series use (anti-SPAG9, then AFP) 45.2 94.4 93.3 50.0 8.13 0.58 39.6

SPAG9, sperm-associated antigen 9; AFP, α-fetoprotein; PPV, positive predictive value; NPV, negative predictive value.